|
|
Profile
|
Delegates :
Taro Tachibana |
|
Incorporated :
February 22 , 2022 |
Paid in Capital :
8 Million yen |
Employees :
2 人 |
Address :
Nishinakajima 5-12-14 mitsuhoshi-bil, Yodogawa-ku, Oosaka-si OSAKA
〒532-0011
|
TEL/FAX :
+81-6-6777-9260 / +81-6-6777-9290 |
URL：
https://www.panctherapy.com/ |
Attachment :
|
Mission/Background :
A biotech startup from Osaka Metropolitan University and Kobe University aiming for early diagnosis and treatment development for pancreatic cancer.
【Our businesses】
・Development of therapeutic agents for pancreatic cancer
・Development of early-stage diagnostic reagents for pancreatic cancer
【Philosophy】
Bringing smiles to patients and families suffering from pancreatic cancer. |
|
Technology & Business
|
We are a biotech startup founded in February 2022, originating from Osaka Metropolitan University (OMU) and Kobe University, specializing in drug seeds for pancreatic cancer treatment and diagnosis. We are developing monoclonal antibodies targeting pancreatic cancer stem cells, as well as those derived from unique patient cases.
Our CEO, who is also a professor at OMU, utilizes the university's advanced monoclonal antibody technologies in our efforts to combat pancreatic cancer.
Our goal is to make significant contributions to the treatment and early diagnosis of pancreatic cancer through the development of these drug discovery seeds and innovative technologies. We are attending BioJapan to introduce our anticancer drug seeds for early licensing opportunities.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Therapeutic antibody seeds for pancreatic cancer stem cells (PT001)
|
Discovery
|
Therapeutic Monoclonal Antibody Seed Targeting Pancreatic Cancer Stem Cells
|
Out-license at the preclinical stage
|
Antibody Seeds Against Pancreatic Cancer Stem Cell-Derived Exosomes (PT002)
|
Discovery
|
Monoclonal Antibody Seed Targeting Exosomes Derived from Pancreatic Cancer Stem Cells
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
PT001: These drug seeds, as antibody-drug conjugate (ADC), are currently being evaluated both in vitro and in vivo. In tumor-bearing mouse models, a significant extension of survival time has been observed compared to the control group.
|
|
Alliance strategy
|
We aim to out-license ‘PT001 ADC (Therapeutic Monoclonal Antibody Seed Targeting Pancreatic Cancer Stem Cells)’ at the preclinical stage and are also looking for collaborative research partners.
Please feel free to get in touch with us.
|
|
|